Rinaldi Riccardo, Spione Francesco, Verardi Filippo Maria, Calés Pablo Vidal, Arévalos Víctor, Gabani Rami, Cánovas Daniel, Gutiérrez Montserrat, Pardo Montserrat, Domínguez Rosa, Pintor Luis, Torres Xavier, Freixa Xavier, Regueiro Ander, Altisent Omar Abdul-Jawad, Sabaté Manel, Brugaletta Salvatore
Hospital Clínic, Instituto Clínic Cardiovascular, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, España Hospital Clínic Instituto Clínic Cardiovascular Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona España.
Dipartimento di Scienze Cardiovascolari e Polmonari, Università Cattolica del Sacro Cuore, Roma, Italia Dipartimento di Scienze Cardiovascolari e Polmonari Università Cattolica del Sacro Cuore Roma Italia.
REC Interv Cardiol. 2024 Jan 30;6(2):67-75. doi: 10.24875/RECIC.M23000420. eCollection 2024 Apr-Jun.
A systematic approach to patients with angina with no obstructed coronary arteries (ANOCA) or ischemia with no obstructed coronary arteries (INOCA) patients is not routinely implemented.
All consecutive patients diagnosed with ANOCA/INOCA were referred to a designated outpatient clinic for a screening visit to assess their eligibility for a NOCA program. If eligible, patients underwent scheduled coronary angiograms with coronary function testing and intracoronary acetylcholine provocation testing. Medical therapy was optimized accordingly. All patients were then followed up at 1, 3, 6, and 12 months. Baseline and 3-month follow-up assessments included the Seattle Angina Questionnaire (SAQ) and EuroQol-5D questionnaire.
Of 77 patients screened, 23 (29.9%) were excluded and 54 (70.1%) were included (29 [53.7%] with INOCA and 25 [46.3%] with ANOCA). Microvascular angina was diagnosed in 19 (35.2%) patients, vasospastic angina in 12 (22.2%), both microvascular angina and vasospastic angina in 18 (33.3%), and noncoronary chest pain in 5 (9.3%). There was a notable increase in the use of beta-blockers, calcium channel blockers and nitrates. Complications occurred in 3 (5.5%) patients. Compared with baseline, there was no difference in the mean EQ-5D score at the 3-month follow-up, but there was a significant improvement in the SAQ score related to physical limitations, angina stability, and disease perception, with no differences in angina frequency or treatment satisfaction. No events were recorded at the 1-year follow-up.
A specific diagnostic and therapeutic protocol can be easily and safely implemented in routine clinical practice, leading to improvement in patients' quality of life.
对于无阻塞性冠状动脉的心绞痛(ANOCA)患者或无阻塞性冠状动脉的心肌缺血(INOCA)患者,尚未常规实施系统的治疗方法。
所有连续诊断为ANOCA/INOCA的患者均被转至指定的门诊进行筛查访视,以评估其是否符合NOCA项目的条件。若符合条件,患者接受 scheduled coronary angiograms with coronary function testing and intracoronary acetylcholine provocation testing。相应地优化药物治疗。然后对所有患者进行1、3、6和12个月的随访。基线和3个月随访评估包括西雅图心绞痛问卷(SAQ)和欧洲五维健康量表(EuroQol-5D)问卷。
在77例接受筛查的患者中,23例(29.9%)被排除,54例(70.1%)被纳入(29例[53.7%]为INOCA,25例[46.3%]为ANOCA)。19例(35.2%)患者被诊断为微血管性心绞痛,12例(22.2%)为血管痉挛性心绞痛,18例(33.3%)同时患有微血管性心绞痛和血管痉挛性心绞痛,5例(9.3%)为非冠状动脉性胸痛。β受体阻滞剂、钙通道阻滞剂和硝酸盐的使用显著增加。3例(5.5%)患者出现并发症。与基线相比,3个月随访时的平均EQ-5D评分无差异,但SAQ评分在身体限制、心绞痛稳定性和疾病认知方面有显著改善,心绞痛频率或治疗满意度无差异。1年随访时未记录到事件。
在常规临床实践中可以轻松、安全地实施特定的诊断和治疗方案,从而改善患者的生活质量。